Aquinnah Pharmaceuticals Massachusetts

Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases

in 2022 to advance oral small molecules for ALS and other neurodegenerative diseases, by modulating TDP-43 pathology, which is the hallmark pathology in more than 95% of ALS patients. Aquinnah has received funding from Pfizer, AbbVie and Takeda, with additional grant funding from the National Institute of Health, the Alzheimer's Association, The Rainwater Foundation and the Mass Life Sciences Center.

About Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is harnessing the power of stress granule biology to develop oral small molecule therapeutics in Neurodegenerative Diseases, focusing on Alzheimer's disease and other tauopathy diseases such as Progressive Supranuclear Palsy and Frontotemporal dementia and ALS, also known as Lou Gehrig's disease, by developing chemical modulators of stress granule pathology. More information is available at www.aquinnahpharma.com.

Logo - https://mma.prnewswire.com/media/2255522/Aquinnah_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/aquinnah-pharmaceuticals-advances-oral-small-molecule-program-targeting-alzheimers-and-other-tauopathy-diseases-301970908.html